-$0.13 Earnings Per Share Expected for Arbutus Biopharma Co. (NASDAQ:ABUS) This Quarter

Equities research analysts expect that Arbutus Biopharma Co. (NASDAQ:ABUSGet Rating) will announce earnings per share of ($0.13) for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Arbutus Biopharma’s earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.15). Arbutus Biopharma reported earnings per share of ($0.23) during the same quarter last year, which indicates a positive year-over-year growth rate of 43.5%. The firm is expected to report its next earnings report on Monday, January 1st.

On average, analysts expect that Arbutus Biopharma will report full year earnings of ($0.51) per share for the current fiscal year, with EPS estimates ranging from ($0.60) to ($0.39). For the next financial year, analysts forecast that the firm will post earnings of ($0.58) per share, with EPS estimates ranging from ($0.80) to ($0.40). Zacks’ EPS averages are an average based on a survey of analysts that cover Arbutus Biopharma.

Arbutus Biopharma (NASDAQ:ABUSGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. Arbutus Biopharma had a negative net margin of 352.49% and a negative return on equity of 121.30%. The company had revenue of $12.58 million during the quarter, compared to analysts’ expectations of $5.77 million. During the same period in the prior year, the company posted ($0.21) earnings per share.

Several equities research analysts have recently weighed in on the stock. Zacks Investment Research cut shares of Arbutus Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, May 16th. Jefferies Financial Group raised shares of Arbutus Biopharma from a “hold” rating to a “buy” rating and increased their target price for the stock from $4.00 to $5.00 in a research note on Wednesday, February 2nd. Chardan Capital increased their target price on shares of Arbutus Biopharma from $5.50 to $6.00 and gave the stock a “buy” rating in a research note on Friday, March 4th. StockNews.com assumed coverage on shares of Arbutus Biopharma in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Finally, HC Wainwright increased their target price on shares of Arbutus Biopharma from $8.00 to $8.50 and gave the stock a “buy” rating in a research note on Monday, March 14th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $6.25.

Several institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. lifted its stake in shares of Arbutus Biopharma by 15.9% in the third quarter. Invesco Ltd. now owns 29,180 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 3,994 shares in the last quarter. ETF Managers Group LLC lifted its stake in shares of Arbutus Biopharma by 13.1% in the fourth quarter. ETF Managers Group LLC now owns 40,934 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 4,727 shares in the last quarter. Citigroup Inc. lifted its stake in shares of Arbutus Biopharma by 53.5% in the third quarter. Citigroup Inc. now owns 14,679 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 5,117 shares in the last quarter. ProShare Advisors LLC lifted its stake in shares of Arbutus Biopharma by 16.3% in the fourth quarter. ProShare Advisors LLC now owns 36,599 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 5,122 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Arbutus Biopharma by 13.6% in the fourth quarter. JPMorgan Chase & Co. now owns 42,737 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 5,126 shares in the last quarter. 26.66% of the stock is currently owned by hedge funds and other institutional investors.

ABUS opened at $2.40 on Friday. Arbutus Biopharma has a twelve month low of $1.93 and a twelve month high of $6.50. The company has a fifty day moving average of $2.66 and a 200-day moving average of $3.13. The stock has a market cap of $356.95 million, a PE ratio of -3.29 and a beta of 2.66.

Arbutus Biopharma Company Profile (Get Rating)

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication.

Further Reading

Get a free copy of the Zacks research report on Arbutus Biopharma (ABUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.